ALBERT

Description: Chronic lymphocytic leukemia (CLL) is a highly variable disorder whose outcome can be predicted by a number of clinical and biological markers. The level of expression of CD38 by peripheral blood leukemic cells is one such prognostic biomarker however despite widespread use in clinical practice, its role in the pathogenesis of CLL remains unclear and an area of active research. A relationship between CD38 expression and proliferation of CLL cells both in the blood and tissues has been demonstrated by several groups and we recently reported that expression is higher in tissues that contain proliferation centers such as splenic white pulp and bone marrow compared to red pulp and peripheral blood which do not. Using an in-vitro model designed to mimic some of the cellular interactions that take place in proliferation centers, we showed that contact with activated autologous CD4+ T cells causes upregulation of CD38 and proliferation of the tumor. In addition, staining of CLL lymph node sections demonstrated that the highest CD38 levels are found in perivascular areas and that overall there are more microvessels in lymph nodes from CD38 positive patients. CD38 expression in CLL is thus linked to tumor proliferation and regulated by interactions in the microenvironment that involve activated T cells and the microvasculature. In order to investigate these interactions, we further developed the in-vitro proliferation center model by incorporating the human microvascular endothelial cell line HMEC-1. CLL cells were incubated for 24–48 hours in the absence or presence of HMEC-1 and/or activated autologous T cells prior to staining for CD19 and CD38 and analysis by flow cytometry. In the presence of HMEC-1, activated T cells or both, CD38 expression by CLL cells increased from an unstimulated mean fluorescence intensity of 3693 to 4747 (n=10, p = 0.001), 18,691 (n= 10, p = 0.03) and 20,729 (n=10, p = 0.01) respectively confirming our previous results and demonstrating an additional effect of endothelial cells. During the course of these experiments it was also noted that HMEC-1 cells markedly improved the viability of the tumor cells. After 7 days, CLL cells purified by negative selection and co-cultured with HMEC-1 had a viability of 86.5%, assessed by flow cytometric measurement of CD19, annexin-V and 7AAD staining, compared to 25.5% in control medium (n=15, p